Abbott LaboratoriesvsExelixis

ABT and EXEL stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$103.94

Value $181B

-0.74%
ABT's page

EXEL

Exelixis, Inc.

$68.88

Value $16.8B

+0.55%
EXEL's page

Abbott Laboratories (ABT) has a market value of $181B and Exelixis (EXEL) $16.8B. The P/E is 38.4 for ABT and 19.0 for EXEL. Dividend yield: ABT 2.42%, EXEL none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$181B

    EXEL$16.8B

    ABT is 11 times EXEL

  • Revenue, 12 months

    ABT$48.2B

    EXEL$2.5B

    ABT is 19 times EXEL

  • Net income, 12 months

    ABT$4.7B

    EXEL$885M

    ABT is 5.3 times EXEL

  • Operating margin

    ABT13.8%

    EXEL40.2%

    26.4 points apart

  • ROIC

    ABT6.3%

    EXEL39.9%

    33.6 points apart

  • P/E

    ABT38.4

    EXEL19.0

    ABT is 2.0 times EXEL

  • Dividend yield

    ABT2.4%

    EXEL0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

Prices are not available right now.

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesEXELExelixis

Valuation

ABTEXEL
Valuation
Price$103.94$68.88
Market value$181B$16.8B
Enterprise value (EV)$207B$15.9B
P/E38.419.0
P/E, 5-year median33.725.4
P/B3.59.2
EV/EBIT31.215.9
Free cash flow yield3.7%6.9%

Results and growth

ABTEXEL
Results and growth
Revenue, 12 months$48.2B$2.5B
Net income, 12 months$4.7B$885M
Free cash flow, 12 months$6.8B$1.2B
Earnings per share, 12 months$2.69$3.34
Revenue growth, year on year5.7%7.0%
Revenue growth a year, past+5.1%over 5 years+18.6%over 5 years
EPS growth a year, past+8.3%over 5 years+51.3%over 5 years

Margins and returns on capital

ABTEXEL
Margins and returns on capital
Gross margin56.9%96.3%
Operating margin13.8%40.2%
Net margin9.8%35.4%
ROIC6.3%39.9%
ROE9.1%44.5%

Balance sheet

ABTEXEL
Balance sheet
Cash$4.3B$892M
Total debt$31.2B$162M
Net debt / EBITDA3.3-0.9
Interest cover6.7×–

Dividends and buybacks

ABTEXEL
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%5.6%
Shareholder yield2.9%5.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or EXEL

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Exelixis?

By market value, Abbott Laboratories ($181B) is about 10.7 times Exelixis ($16.8B), at today's prices.

Which pays the higher dividend, ABT or EXEL?

The dividend yield at today's price is 2.42% for Abbott Laboratories and none for Exelixis. Over the last twelve months they paid $2.52 and – per share.

What is the P/E of ABT and EXEL?

At today's price, the P/E is 38.4 for ABT and 19.0 for EXEL. The median of the last five years was 33.7 and 25.4, which shows where each stands against its own past.

Which has the higher profit margins, Abbott Laboratories or Exelixis?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 35.4% for Exelixis, and the operating margin 13.8% and 40.2%. Revenue was $48.2B and $2.5B.

Which is the better investment, Abbott Laboratories or Exelixis?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.